{"id":410261,"date":"2021-01-07T08:03:17","date_gmt":"2021-01-07T13:03:17","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=410261"},"modified":"2021-01-07T08:03:17","modified_gmt":"2021-01-07T13:03:17","slug":"neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/","title":{"rendered":"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SEATTLE, Jan.  07, 2021  (GLOBE NEWSWIRE) &#8212; Neoleukin Therapeutics, Inc., \u201cNeoleukin\u201d (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design\u00a0de novo\u00a0protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the 39<sup>th<\/sup> Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:30 p.m. Eastern Time.<\/p>\n<p>A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=rqF-pJt4uKNH90CP06wLYUztnD-2fOjfiTNO2vngNHcGhs43C40yxwfU-1xXVPWKWktwKu4PZ7vn6jBeUtiByW7fDzNFVw0wPCBIOhYdhMnObqaaCCbnPz-noGz-G3Sj\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>http:\/\/investor.neoleukin.com\/events<\/u><\/a>. An archived replay will also be available on the company website for at least 30 days following the event.<\/p>\n<p>\n        <strong>About Neoleukin Therapeutics, Inc.<\/strong>\n      <\/p>\n<p>Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using\u00a0de novo\u00a0protein design technology. Neoleukin uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins.\u00a0 Neoleukin\u2019s lead product candidate, NL-201, is a combined IL-2 and IL-15 agonist designed to improve tolerability and activity by eliminating the alpha receptor binding interface. For more information, please visit the Neoleukin website:\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=s-d5ZoGICTu5NsA93tm1T1vGU-YdEFa5hjMH370q6awTTyFPFcphWGkUOv-fb4VBFtMIUxCyN0d-tGlvZJJKwg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">www.neoleukin.com<\/a>.<\/p>\n<p align=\"justify\">\n        <strong>Safe Harbor \/ Forward-Looking Statements <\/strong>\n      <\/p>\n<p>This press release contains &#8220;forward-looking&#8221; statements within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, but not limited to, planned development activities and timelines, and the therapeutic properties and potential benefits of the company\u2019s product candidates and <em>de novo<\/em> protein design technology. Forward-looking statements can be identified by words such as: &#8220;anticipate,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;goal,&#8221; &#8220;seek,&#8221; &#8220;believe,&#8221; &#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;strategy,&#8221; &#8220;future,&#8221; &#8220;likely,&#8221; &#8220;may,&#8221; &#8220;should,&#8221; &#8220;will&#8221; and similar references to future periods. These statements are subject to numerous risks and uncertainties, including risks and uncertainties related to the company\u2019s cash forecasts, the company\u2019s ability to advance its product candidates, the receipt and timing of potential regulatory submissions, designations, approvals and commercialization of product candidates, the timing and results of preclinical and clinical trials, the timing of announcements and updates relating to the company\u2019s clinical trials and related data market conditions and further impacts of COVID-19, that could cause actual results to differ materially from what Neoleukin expects. Further information on potential risk factors that could affect Neoleukin\u2019s business and its financial results are detailed under the heading \u201cRisk Factors\u201d in documents the company files from time to time with the\u00a0Securities and Exchange Commission\u00a0(SEC), and other reports as filed with the\u00a0SEC. Neoleukin undertakes no obligation to publicly update any forward-looking statement, whether written or oral, that may be made from time to time, whether as a result of new information, future developments or otherwise.<\/p>\n<p>\n        <strong>Contacts: <\/strong>\n      <\/p>\n<p>\n        <strong>Media<\/strong><br \/>\n        <br \/>Julie Rathbun<br \/>206-769-9219<br \/>jrathbun@neoleukin.com<\/p>\n<p>\n        <strong>Investors<\/strong><br \/>\n        <br \/>Solebury Trout<br \/>Brian Korb<br \/>646-378-2923<br \/>bkorb@troutgroup.com<\/p>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/70d601de-d7e0-4c76-989e-e5d29ca0b24d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Neoleukin Therapeutics, Inc., \u201cNeoleukin\u201d (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design\u00a0de novo\u00a0protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:30 p.m. Eastern Time. A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at http:\/\/investor.neoleukin.com\/events. An archived replay will also be available on the company website for at least 30 days following the event. About Neoleukin Therapeutics, Inc. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using\u00a0de novo\u00a0protein &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-410261","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Neoleukin Therapeutics, Inc., \u201cNeoleukin\u201d (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design\u00a0de novo\u00a0protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:30 p.m. Eastern Time. A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at http:\/\/investor.neoleukin.com\/events. An archived replay will also be available on the company website for at least 30 days following the event. About Neoleukin Therapeutics, Inc. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using\u00a0de novo\u00a0protein &hellip; Continue reading &quot;Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-07T13:03:17+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference\",\"datePublished\":\"2021-01-07T13:03:17+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/\"},\"wordCount\":470,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/\",\"name\":\"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=\",\"datePublished\":\"2021-01-07T13:03:17+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference - Market Newsdesk","og_description":"SEATTLE, Jan. 07, 2021 (GLOBE NEWSWIRE) &#8212; Neoleukin Therapeutics, Inc., \u201cNeoleukin\u201d (NASDAQ:NLTX), a biopharmaceutical company utilizing sophisticated computational methods to design\u00a0de novo\u00a0protein therapeutics, today announced that Jonathan Drachman, M.D., Chief Executive Officer, will present at the 39th Annual J.P. Morgan Virtual Healthcare Conference on Thursday, January 14, 2021 at 4:30 p.m. Eastern Time. A live audio webcast of the corporate presentation and question and answer session to follow will be available from the investors section of the Neoleukin website at http:\/\/investor.neoleukin.com\/events. An archived replay will also be available on the company website for at least 30 days following the event. About Neoleukin Therapeutics, Inc. Neoleukin is a biopharmaceutical company creating next generation immunotherapies for cancer, inflammation and autoimmunity using\u00a0de novo\u00a0protein &hellip; Continue reading \"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-07T13:03:17+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference","datePublished":"2021-01-07T13:03:17+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/"},"wordCount":470,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/","name":"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=","datePublished":"2021-01-07T13:03:17+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODEyMTg1MyMzOTA4MDI3IzIyMDMxNzU="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/neoleukin-therapeutics-to-present-at-j-p-morgan-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Neoleukin Therapeutics to Present at J.P. Morgan Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410261","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=410261"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/410261\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=410261"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=410261"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=410261"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}